U.S. Capital Wealth Advisors’s AbbVie ABBV Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.5M	Buy	52,656 +3,297	+7%	+$731K	0.29%	76
2025 Q4	$11.3M	Buy	49,359 +1,721	+4%	+$392K	0.29%	78
2025 Q3	$11M	Sell	47,638 -21,256	-31%	-$4.33M	0.3%	81
2025 Q2	$12.8M	Sell	68,894 -17,458	-20%	-$3.24M	0.37%	61
2025 Q1	$18.1M	Sell	86,352 -44,566	-34%	-$8.66M	0.55%	37
2024 Q4	$23.3M	Buy	130,918 +3,120	+2%	+$574K	0.72%	18
2024 Q3	$25.2M	Sell	127,798 -903	-0.7%	-$169K	0.89%	15
2024 Q2	$22.1M	Sell	128,701 -883	-0.7%	-$146K	0.84%	17
2024 Q1	$23.6M	Sell	129,584 -18,249	-12%	-$3.15M	0.91%	19
2023 Q4	$22.9M	Sell	147,833 -45,031	-23%	-$6.57M	0.91%	16
2023 Q3	$28.7M	Sell	192,864 -4,399	-2%	-$646K	1.29%	9
2023 Q2	$26.6M	Sell	197,263 -11,524	-6%	-$1.69M	1.26%	9
2023 Q1	$33.3M	Buy	208,787 +5,541	+3%	+$847K	1.54%	8
2022 Q4	$32.8M	Sell	203,246 -21,116	-9%	-$3.24M	1.52%	7
2022 Q3	$30.1M	Buy	224,362 +1,791	+0.8%	+$257K	1.52%	7
2022 Q2	$34.1M	Sell	222,571 -13,385	-6%	-$2.05M	1.5%	7
2022 Q1	$38.3M	Sell	235,956 -5,966	-2%	-$867K	1.4%	9
2021 Q4	$32.8M	Sell	241,922 -15,640	-6%	-$1.85M	1.3%	9
2021 Q3	$27.8M	Buy	+257,562	New	+$29.4M	1.21%	10

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

U.S. Capital Wealth Advisors's ABBV Position: Q1 2026 in Review

U.S. Capital Wealth Advisors increased its AbbVie (ABBV) stake by 6.7% in Q1 2026, buying an estimated $731K and bringing the position to 52,656 shares worth $11.5M. The position accounts for 0.29% of the portfolio, ranked #76.

U.S. Capital Wealth Advisors first reported a position in ABBV in Q3 2021 and has held it in 19 quarters since. The position peaked at $38.3M in Q1 2022. 4,102 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

U.S. Capital Wealth Advisors held 52,656 shares of AbbVie worth $11.5M as of Q1 2026.
U.S. Capital Wealth Advisors bought 3,297 AbbVie shares in Q1 2026, an estimated $731K.
AbbVie made up 0.29% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #76 holding.
U.S. Capital Wealth Advisors first reported a position in AbbVie in Q3 2021 and has held it in 19 quarters since.
U.S. Capital Wealth Advisors's AbbVie position peaked at $38.3M in Q1 2022.
4,102 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.